Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Nov 1;5:39. doi: 10.1038/s41523-019-0135-5

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2019

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 9 — The combination of LG268 and anti-PD-L1 antibodies increases the infiltration of CD8 T cells and caspase 3 activation. a Experimental design. PyMT mice with tumor(s) 32–64 mm³ in size were started on control diet or LG268 diet (100 mg/kg) 48 h before the first anti-PD-L1 treatment. Anti-PD-L1 antibodies were injected i.p. (three injections each of 40 µg per mouse). Mice were killed on day 15. (n = 7 mice/group). b Immune cell infiltration in tumors was analyzed by flow cytometry. Total T cells: CD45⁺, CD3⁺; CD4 T cells: CD45⁺, CD3⁺, CD4⁺; activated CD4 T cells: CD45⁺, CD3⁺, CD4⁺, CD25⁺; CD8 T cells: CD45⁺, CD3⁺, CD8⁺ (t = 2.219; df = 12) (ratio %CD8/%CD4, CD25: t = 2.268; df = 12). c Immunohistochemistry for PD-L1, CD8 and cleaved caspase 3 in tumors. Scale bar represents 60 μm. n = 5–7, bars represent average and error bars the standard error of the mean (SEM)